Mutant epidermal growth factor receptor undergoes less protein degradation due to diminished binding to c-Cbl

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Gefitinib (Iressa) sensitivity in non-small cell lung cancer (NSCLC) correlates with activating mutations in epidermal growth factor receptor (EGFR).
• Mutant EGFR exhibits prolonged autophosphorylation compared to wild-type EGFR, suggesting a potential mechanism for drug resistance.

Purpose of the Study:

• To investigate the mechanism underlying the sustained autophosphorylation of mutant EGFR.
• To compare the protein degradation rates of wild-type and mutant EGFR in NSCLC cell lines.

Main Methods:

• EGFR degradation activity was assessed using 125I-EGF in NSCLC cell lines (PC-9 with mutant EGFR and PC-14 with wild-type EGFR).
• Stable transfected cell lines (293_pEGFR for wild-type and 293_pdelta15 for mutant EGFR) were utilized to further elucidate the degradation pathways.
• Binding affinity of c-Cbl ubiquitin ligase to EGFR was evaluated in the transfected cell lines.

Main Results:

• EGFR exhibited a lower degradation rate in the PC-9 NSCLC cell line (carrying a 15-bp deletion mutant EGFR) compared to the PC-14 cell line (wild-type EGFR).
• In the 293_pdelta15 cell line expressing mutant EGFR, both EGFR degradation and the binding of c-Cbl ubiquitin ligase were significantly reduced compared to the 293_pEGFR cell line (wild-type EGFR).

Conclusions:

• Mutant EGFR undergoes reduced protein degradation.
• This diminished degradation is attributed to impaired binding with the c-Cbl ubiquitin ligase.
• The findings provide mechanistic insight into sustained EGFR signaling in NSCLC, potentially impacting gefitinib sensitivity.